WHWK
Whitehawk Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Buy
2.0 / 5
5 analysts
$4.30
(0.00%)
Target:
$7.20
(67.4%)
Sign in to add WHWK to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $212.65M |
| P/E Ratio (TTM) | - |
| Forward P/E | -3.69 |
| EPS (TTM) | $-2.49 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -68.54% |
| Debt/Equity | - |
| Recommendation | Buy 2.0 |
| Analyst Target | $7.20 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 57.2 |
| Beta | 0.77 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $5.50 |
| 52-Week Low | $1.57 |
| 50-Day Avg | $4.28 |
| 200-Day Avg | $3.12 |
| Avg Volume | 417.5K |
| Volume | 40.3K |
Performance Analysis
BULLISHWHWK shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 70% of its 52-week range.
+
RSI at 57.2 shows positive momentum.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
+
Wall Street consensus is "Buy" from 5 analysts.
+
Average analyst target of $7.20 implies 67.4% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:37 UTC
Back to Screener Export Report